Publications

A listing of recent selected publications appears below. For a comprehensive list of Dr. Waller's publications, visit PubMed or ResearchGate.

VPAC2 Receptor Signaling Promotes Growth and Immunosuppression in Pancreatic Cancer.
Passang T, Wang S, Zhang H, Zeng F, Hsu PC, Wang W, Li JM, Liu Y, Ravindranathan S, Lesinski GB, Waller EK. Cancer Res. 2024 Sep 16;84(18):2954-2967.

The magic of small-molecule drugs during ex vivo expansion in adoptive cell therapy.
Zhang H, Passang T, Ravindranathan S, Bommireddy R, Jajja MR, Yang L, Selvaraj P, Paulos CM, Waller EK. Front Immunol. 2023 Apr 21;14:1154566.

Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma.
Ravindranathan S, Passang T, Li JM, Wang S, Dhamsania R, Ware MB, Zaidi MY, Zhu J, Cardenas M, Liu Y, Gumber S, Robinson B, Sen-Majumdar A, Zhang H, Chandrakasan S, Kissick H, Frey AB, Thomas SN, El-Rayes BF, Lesinski GB, Waller EK. Nat Commun. 2022 Oct 27;13(1):6418.

Donor plasmacytoid dendritic cells limit graft-versus-host disease through vasoactive intestinal polypeptide expression.
Zhu J, Wang Y, Li J, Das PK, Zhang H, Passang T, Li JM, Nagy T, Gandhi K, Ravindranathan S, Giver CR, Hassan M, Li Y, Antonova AU, Wang S, Roback JD, Waller EK. Blood. 2022 Sep 22;140(12):1431-1447.

Comparing VIP and PD-L1 expression as cancer biomarkers.
Liu JY, Zhang H, Ravindranathan S, Owonikoko T, El-Rayes B, Liu Y, Waller EK. ImmunoMedicine. 2022 July; 2(2):e1033.

PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.
Funk CR, Wang S, Chen KZ, Waller A, Sharma A, Edgar CL, Gupta VA, Chandrakasan S, Zoine JT, Fedanov A, Raikar SS, Koff JL, Flowers CR, Coma S, Pachter JA, Ravindranathan S, Spencer HT, Shanmugam M, Waller EK. Blood. 2022 Jan 27;139(4):523-537.

Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and -γ.
Chandrasekaran S, Funk CR, Kleber T, Paulos CM, Shanmugam M, Waller EK. Front Immunol. 2021 Aug 26;12:718621.

Kinetics of immune cell reconstitution predict survival in allogeneic bone marrow and G-CSF-mobilized stem cell transplantation.
Waller EK, Logan BR, Fei M, Lee SJ, Confer D, Howard A, Chandrakasan S, Anasetti C, Fernando SM, Giver CR. Blood Adv. 2019 Aug 13;3(15):2250-2263

Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report.
Funk CR, Petersen CT, Jagirdar N, Ravindranathan S, Jaye DL, Flowers CR, Langston A, Waller EK. Int J Mol Sci. 2018 Dec 19;19(12):4118.

Flt3L Treatment of Bone Marrow Donors Increases Graft Plasmacytoid Dendritic Cell Content and Improves Allogeneic Transplantation Outcomes.
Hassan M, Ulezko Antonova A, Li JM, Hosoba S, Rupji M, Kowalski J, Perricone AJ, Jaye DL, Marsh H, Yellin M, Devine S, Waller EK. Biol Blood Marrow Transplant. 2019 Jun;25(6):1075-1084.

Indoles derived from intestinal microbiota act via type I interferon signaling to limit Graft-versus-Host-Disease.
Swimm A, Giver CR, DeFilipp Z, Rangaraju S, Sharma A, Ulezko Antonova A, Sonowal R, Capaldo C, Powell D, Qayed M, Kalman D, Waller EK.
Blood. 2018 Sep 26. pii: blood-2018-03-838193. doi: 10.1182/blood-2018-03-838193. [Epub ahead of print]

Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists.
Petersen CT, Hassan M, Morris AB, Jeffery J, Lee K, Jagirdar N, Staton AD, Raikar SS, Spencer HT, Sulchek T, Flowers CR, Waller EK.
Blood Adv. 2018 Feb 13;2(3):210-223.

Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Hosoba S, Waller EK, Shenvi N, Graiser M, Easley KA, Al-Kadhimi Z, Andoh A, Antun AG, Barclay S, Josephson CD, Koff JL, Khoury HJ, Langston AA, Zimring JC, Roback JD, Giver CR.
Biol Blood Marrow Transplant. 2018 May;24(5):973-982.